Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- BBRY +7.7%, THO +4.1%, MKC +2.7%, JBL +0.6%
M&A news:
- ADHD +12.6% (Alcobra and Arcturus Therapeutics, Inc. agreed to merge in all stock transaction; conversion ratio for the transaction is based on a valuation of Alcobra of $46.7 million)
- AAAP +11.5% (potential NVS M&A deal)
Other news:
- ZYNE +93.1% (top line results from an open label exploratory Phase 2 FAB-C clinical trial), VTGN +12.8% (receives a NOA from the USPTO for patent related to certain methods of production for AV-101), CHMA+10.2% (announced the randomization of first patient in its new Phase 3 trial referred to as 'CHIASMA OPTIMAL', 'meeting its previous guidance'; also surpassed 50% patients randomized in its international Phase 3 clinical trial), ADVM +10.1% (presents updated preclinical data on ADVM-022 in Wet AMD at conference; data continue to demonstrate the durability and safety of a novel gene therapy approach ), MARK+9.2% (awarded a multimillion-dollar contract by Sefon), SPPI +7.1% (releases an abstract from a clinical study evaluating poziotinib in EGFR Exon 20 Mutant NSCLC ABT +3.8% ( confirms the FDA approved the FreeStyle Libre Flash Glucose Monitoring System as a replacement1 for blood glucose monitoring for adults with diabetes ),CLDR +1.3% (prices follow-on public offering of its common stock pursuant at $16.45 per share)
Analyst comments:
- SYRS +3.6% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- MNK +3.4% (initiated with a Buy at Goldman)
- HZNP +3% (initiated with a Buy at Goldman)
- POT +1% (upgraded to Buy at TD Securities)
- MCD +1% (upgraded to Buy from Neutral at Longbow)
- HUN +1% (upgraded to Outperform from Market Perform at Wells Fargo)
- PM +0.9% (added to Conviction Buy List at Goldman)